Pacira Pharmaceuticals
United States Updated 9 July 2026
Pacira Pharmaceuticals is a finished-dose manufacturer based in United States. It appears in 3 regulatory filings across 1 regulator, without an active US DMF or CEP on file. Its GMP standing is certified by MHRA (UK). Its most recent recorded inspection, by US FDA, closed on 19 April 2023 as VAI.
3
registered plants
1 with an FDA FEI number
3
filings
across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 19 April 2023 VAI US FDA
- 1 March 2018 VAI US FDA
- 22 July 2015 VAI US FDA
- 10 February 2014 VAI US FDA
- 27 March 2013 VAI US FDA
- 23 February 2012 VAI US FDA
- 17 June 2011 VAI US FDA
- 24 January 2011 NAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| SAN DIEGO, United States | Not on file |
| SAN DIEGO, United States | Not on file |
| San Diego, United States | 3002783962 |
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| US FDA | 3 | None |
| MHRA (UK) | None | 2 |
Comparing suppliers?
Choose your molecules and target markets. Pacira Pharmaceuticals comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was VAI, on 19 April 2023.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates